A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Double Lung Transplant
Latest Information Update: 02 May 2025
At a glance
- Drugs Ciclosporin (Primary)
- Indications Bronchiolitis obliterans
- Focus Registrational; Therapeutic Use
- Acronyms BOSTON-2
- Sponsors Breath Therapeutics; Zambon Company SpA
Most Recent Events
- 27 Jan 2025 Status changed from active, no longer recruiting to completed.
- 08 Jul 2024 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 12 Jun 2024 This trial has been completed in Austria (Global end date-12 Mar 2024).